Regeneron Donates Ebola Treatment for Use in Countries Most at Risk of Outbreaks

Inmazeb^® (atoltivimab, maftivimab, and odesivimab-ebgn) was the first treatment approved by the U.S. Food and Drug Administration (FDA) for Orthoebolavirus zairense, also known as Zaire ebolavirus